###begin article-title 0
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in Vivo</italic>
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">S&#8414;</xref>
Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5*Sâƒž
###end article-title 0
###begin p 1
###xml 242 263 242 263 <email xmlns:xlink="http://www.w3.org/1999/xlink">c.r.wolf@dundee.ac.uk</email>
 To whom correspondence should be addressed: Cancer Research UK Molecular Pharmacology Unit, Biomedical Research Institute, Level 5, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. Tel.: 44-1382-632621; Fax: 44-1382-66993; E-mail: c.r.wolf@dundee.ac.uk. 
###end p 1
###begin p 2
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 393 394 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 453 454 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 534 542 534 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 651 652 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 652 653 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 863 870 863 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1280 1281 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1281 1282 1281 1282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1341 1342 1341 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1342 1343 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1373 1380 1373 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 460 465 <span type="species:ncbi:10090">mouse</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 1288 1292 <span type="species:ncbi:10090">mice</span>
In vitro, cytochrome b5 modulates the rate of cytochrome P450-dependent mono-oxygenation reactions. However, the role of this enzyme in determining drug pharmacokinetics in vivo and the consequential effects on drug absorption distribution, metabolism, excretion, and toxicity are unclear. In order to resolve this issue, we have carried out the conditional deletion of microsomal cytochrome b5 in the liver to create the hepatic microsomal cytochrome b5 null mouse. These mice develop and breed normally and have no overt phenotype. In vitro studies using a range of substrates for different P450 enzymes showed that in hepatic microsomal cytochrome b5 null NADH-mediated metabolism was essentially abolished for most substrates, and the NADPH-dependent metabolism of many substrates was reduced by 50-90%. This reduction in metabolism was also reflected in the in vivo elimination profiles of several drugs, including midazolam, metoprolol, and tolbutamide. In the case of chlorzoxazone, elimination was essentially unchanged. For some drugs, the pharmacokinetics were also markedly altered; for example, when administered orally, the maximum plasma concentration for midazolam was increased by 2.5-fold, and the clearance decreased by 3.6-fold in hepatic microsomal cytochrome b5 null mice. These data indicate that microsomal cytochrome b5 can play a major role in the in vivo metabolism of certain drugs and chemicals but in a P450- and substrate-dependent manner.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 5
###begin p 6
###xml 27 55 27 55 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Cancer Research UK Programme</grant-sponsor>
###xml 62 73 62 73 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">C4639/A5661</grant-num>
###xml 230 243 230 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported by Cancer Research UK Programme Grant C4639/A5661 (to C. R. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 6
###begin p 7
The on-line version of this article (available at ) contains supplemental Figs. 1-5 and Tables 1-5.
###end p 7
###begin p 8
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 134 136 134 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b<sub>5</sub></italic>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
Microsomal cytochrome b5 is a 15.2-kDa hemoprotein, located in the endoplasmic reticulum with its obligate electron donor, cytochrome b5 reductase. This protein is involved in fatty acid desaturation, reactivation of methemoglobin to hemoglobin, and electron transfer into the cytochrome P450 system (1-4).
###end p 8
###begin p 9
###xml 23 24 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 232 233 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 476 477 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 497 499 497 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b<sub>5</sub></italic>
###xml 529 537 529 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 715 716 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 789 790 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 790 791 790 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 970 971 970 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">2</xref>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1028 1029 1028 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1029 1030 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1042 1043 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1043 1044 1043 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1191 1197 1191 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 1199 1200 1199 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 1226 1227 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1227 1228 1227 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1465 1466 1465 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1466 1467 1466 1467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1469 1471 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 568 573 <span type="species:ncbi:9606">human</span>
The role of cytochrome b5 in cytochrome P450 monooxygenase reactions has been controversial for nearly 40 years (5, 6). Depending on the cytochrome P450 involved, the experimental conditions, and the substrate utilized, cytochrome b5 has been shown to stimulate or inhibit cytochrome P450 reactions (2, 6). Indeed, in the case of cytochrome P450 CYP2B4, activity can be both stimulated or inhibited by the presence of the enzyme, depending on the concentration of cytochrome b5 (7, 8). Cytochrome b5 has been shown to affect the in vitro activities of a wide range of human P450s, such as CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, as well as the metabolism of an extensive number of commonly used drugs (9, 10). Although the mechanism(s) of the stimulatory effect of cytochrome b5 on P450 metabolism appear complex, it is widely accepted that the P450 catalytic cycle involves the sequential transfer of two electrons from NADPH via P450 oxidoreductase (POR).2 Hildebrandt and Estabrook (5) concluded that cytochrome b5/cytochrome b5 reductase was able to supply the second (rate-limiting) electron from NADH and possibly in a more rapid manner. However, recent data from Waskell et al. (8) suggest that cytochrome b5 and POR are capable of reducing P450s at much the same rate, albeit that overall catalysis occurs more slowly with POR, leading to speculation that the oxyferrous form of P450 may exist in different conformations with POR or cytochrome b5 (11).
###end p 9
###begin p 10
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 96 97 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 453 454 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
A noncatalytic (i.e. allosteric) role has also been proposed for the interaction of cytochrome b5 with cytochrome P450, based on reports that apocytochrome b5 (i.e. without the heme prosthetic group) can stimulate P450 catalysis (1, 12, 13). Although these findings have been debated (14-16) and appear to depend upon the enzyme studied, the mechanism(s) underlying such allosteric effects remains uncertain. It does seem clear however, that cytochrome b5 binding can cause conformational changes to the substrate access channel and binding pocket in the P450 enzyme (1, 17). In many cases, allosteric stimulation increases P450 activity by a relatively small amount, and the physiological relevance of this effect, if any, is unclear (6).
###end p 10
###begin p 11
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 173 180 173 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 221 229 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 297 298 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 390 391 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 346 351 <span type="species:ncbi:9606">human</span>
All studies on cytochrome b5 to date have been carried out in vitro; the in vivo relevance of these findings has remained unknown (9, 10, 17-20). Although the prediction of in vivo drug pharmacokinetic data obtained from in vitro experiments rarely takes the potential contribution of cytochrome b5 into account, a recent study using recombinant human P450s did find that using cytochrome b5 yielded a more accurate estimate of intrinsic clearance (21).
###end p 11
###begin p 12
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 232 233 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 284 285 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 285 286 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 328 336 328 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
In order to establish the relevance of the in vitro observations to those in vivo and to evaluate whether variability in cytochrome b5 levels may affect rates of drug metabolism, we have conditionally deleted microsomal cytochrome b5 in the liver. Using hepatic microsomal cytochrome b5 null (HBN) mice, we demonstrate that the in vitro rate of NADPH- and NADH-dependent metabolism of a range of both model substrates and probe drugs is markedly changed. Furthermore, we show that when probe drugs are administered to mice, significant changes in drug pharmacokinetics occur.
###end p 12
###begin title 13
EXPERIMENTAL PROCEDURES
###end title 13
###begin p 14
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chemicals</italic>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
Chemicals-All reagents unless stated were purchased from Sigma. NADPH was obtained from Melford Laboratories (Ipswich, UK). Bufuralol, 1'-hydroxybufuralol, 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-methoxy-4-trifluoromethylcoumarin (MFC), 7-hydroxy-4-trifluoromethylcoumarin, and hydroxytolbutamide were purchased from BD Gentest (Cowley, UK). Midazolam, 1-hydroxymidazolam, and 4-hydroxymidazolam were kind gifts from Roche Applied Science, and 1-hydroxymetoprolol and O-demethylmetoprolol were generous gifts from Astra Hasle (Molndal, Sweden).
###end p 14
###begin p 15
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 0 56 0 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Generation of Hepatic Microsomal Cytochrome b<sub>5</sub> Null Mice</italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 276 277 276 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 1070 1072 1070 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/</sup>
###xml 1072 1075 1072 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox</sup>
###xml 1072 1075 1072 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>lox</sup></italic>
###xml 1075 1076 1075 1076 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1336 1337 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1337 1339 1337 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/</sup>
###xml 1339 1342 1339 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox</sup>
###xml 1339 1342 1339 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>lox</sup></italic>
###xml 1342 1343 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1373 1374 1373 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1457 1460 1457 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
###xml 180 185 <span type="species:ncbi:10090">mouse</span>
###xml 258 263 <span type="species:ncbi:10090">mouse</span>
###xml 1164 1168 <span type="species:ncbi:10090">mice</span>
###xml 1184 1188 <span type="species:ncbi:10090">mice</span>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
Generation of Hepatic Microsomal Cytochrome b5 Null Mice-A targeting vector was constructed from an 18-kb DNA fragment, produced by fusing overlapping PCR fragments generated from mouse 129/Ola genomic DNA (supplemental Fig. 1A), containing exons 2-5 of the mouse cytochrome b5 gene. A cassette, flanked by same orientation loxP sites and containing a selectable marker (neomycin), driven by the herpes simplex thymidine kinase promoter, was cloned into a BclI site in intron 1, and a third loxP site was cloned into a KpnI site in intron 5. The construct was checked by PCR and sequencing and transfected into GK129/1 embryonic stem cells by electroporation; the embryonic stem cells were subsequently cultured in 96-well plates under G418 selection. G418-resistant clones were screened for specific homologous recombination by Southern blot analysis, using BglII and an 800-bp PCR fragment generated using 5'-GGCACAACACCAATTATTTGTC-3' and 5'-GACAGTCCTTAACACAAGCTC-3' as forward and reverse primers, respectively. Two correctly targeted embryonic stem cell clones (Cytb+/lox5) were expanded, injected into C57BL/6 blastocysts, and transferred into pseudopregnant mice. Male chimeric mice were bred to C57BL/6 mice, and heterozygous offspring were screened by Southern blot and multiplex PCR to confirm germ line transmission of the Cytb+/lox5 genotype (supplemental Fig. 1B) using the following primer set: 1) forward primer, 5'-CCAATGGTCTCTCCTTGGTC-3';2) lox/neomycin reverse primer, 5'-CAATAGCAGCCAGTCCCTTC-3'; 3) wild-type reverse primer, 5'-GATGGAGTTCCCCGATGAT-3'.
###end p 15
###begin p 16
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mouse Breeding and Maintenance</italic>
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox</sup>
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb<sub>5</sub><sup>lox</sup></italic>
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">/+</sup>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 87 94 87 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 180 187 180 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 180 187 180 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 332 335 332 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 371 375 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 375 376 375 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 376 379 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 376 381 376 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox</italic>/+</sup>
###xml 386 389 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 383 389 383 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>ALB</sup></italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 426 427 426 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 427 434 427 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 427 434 427 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 490 491 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 529 530 529 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 530 537 530 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 525 537 525 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb<sub>5</sub><sup>lox/lox</sup></italic>
###xml 542 545 542 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 539 545 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>ALB</sup></italic>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 575 576 575 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 576 583 576 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 576 583 576 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 697 700 697 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 307 310 <span type="species:ncbi:10116">rat</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
Mouse Breeding and Maintenance-Cytb5lox/+ mice were crossed to produce homozygous Cytb5lox/lox mice and maintained by random breeding on a 129P2 x C57BL/6 genetic background. Cytb5lox/lox mice were crossed with a transgenic mouse line expressing Cre recombinase under the control of the hepatocyte-specific rat albumin promoter (CreALB) (22) on a C57BL/6 background, and Cytb5lox/+::CreALB offspring were backcrossed with Cytb5lox/lox mice to generate liver-specific microsomal cytochrome b5 conditional knock-out mice (HBN; Cytb5lox/lox::CreALB) and control (wild-type, Cytb5lox/lox) mice. The HBN line was thereafter maintained by random intercrossing of these two lines. The presence of the CreALB transgene was determined as previously described (23).
###end p 16
###begin p 17
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
All mice were maintained under standard animal house conditions, with free access to food and water, and a 12-h light/12-h dark cycle. All animal work was carried out on male 10-week-old mice in accordance with the Animal Scientific Procedures Act (1986) and after local ethical review.
###end p 17
###begin p 18
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vivo Drug Treatments</italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
In Vivo Drug Treatments-HBN and wild-type mice were administered the following drugs either concomitantly as a mixture or individually: chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg), dissolved in mixture buffer (5% ethanol, 5% DMSO, 35% polyethylene glycol 200, 40% phosphate buffered saline, and 15% water), by intravenous injection or orally by gavage.
###end p 18
###begin p 19
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of Microsomes</italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Preparation of Microsomes-Microsomes were prepared from wild-type and HBN mouse tissues, using 0.3-0.5 g of tissue, by a modified method of Meehan et al. (24), using sonication instead of mechanical homogenization (25). Microsomal protein concentrations were determined using the Bio-Rad protein assay reagent. POR activity was estimated by NADPH-dependent cytochrome c reduction (26). Microsomes were stored at -70 degreesC until required.
###end p 19
###begin p 20
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblotting</italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 304 305 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">3</xref>
###xml 425 426 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 424 426 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b<sub>5</sub></italic>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 134 137 <span type="species:ncbi:10116">rat</span>
###xml 153 156 <span type="species:ncbi:10116">rat</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
###xml 288 291 <span type="species:ncbi:10116">rat</span>
###xml 357 360 <span type="species:ncbi:10116">rat</span>
###xml 583 587 <span type="species:ncbi:9925">goat</span>
###xml 593 599 <span type="species:ncbi:9986">rabbit</span>
###xml 606 611 <span type="species:ncbi:10090">mouse</span>
###xml 621 626 <span type="species:ncbi:9940">sheep</span>
###xml 627 638 <span type="species:ncbi:3704">horseradish</span>
###xml 764 775 <span type="species:ncbi:3704">horseradish</span>
Immunoblotting-Western blot analysis was carried out as previously described using polyclonal antisera raised against human POR (27); rat cytochrome b5; rat CYP2A1, CYP2B1, CYP2C6, CYP3A1, and CYP4A1 (28); or human full-length CYP2A4, CYP2D6, and CYP2E1 (25, 29). Polyclonal antiserum to rat cytochrome b5 reductase and a monoclonal antibody raised against rat CYP1A1 were also used.3 The polyclonal antiserum to cytochrome b5 oxidoreductase was a kind gift from Dr. Hao Zhu (Kansas University Medical Center, Kansas City, KS). Immunoreactive proteins were detected using polyclonal goat anti-rabbit, anti-mouse, or anti-sheep horseradish peroxidase immunoglobulins as secondary antibodies (Dako, Ely, UK) and visualized using Immobilontrade mark chemiluminescent horseradish peroxidase substrate (Millipore, Watford, UK) and a FUJIFILM LAS-3000 mini-imaging system (Fujifilm UK Ltd.). Densitometric analysis was performed using Multi Gauge version 2.2 software (Fujifilm UK Ltd.).
###end p 20
###begin p 21
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Generic Microsomal Incubations</italic>
###xml 92 93 92 93 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 113 114 113 114 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 306 307 300 301 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 132 137 <span type="species:ncbi:10090">mouse</span>
Generic Microsomal Incubations-Microsomal incubations were carried out in triplicate in 50 mm Hepes, pH 7.4, 30 mm MgCl2 containing mouse liver microsomes and substrate prewarmed to 37 degreesC before initiation of the reaction by the addition of either NADPH or NADH to a final concentration of 0.5 or 1 mm, respectively.
###end p 21
###begin p 22
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fluorogenic Assay Incubations</italic>
###xml 176 177 174 175 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 233 234 229 230 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 291 292 285 286 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 393 394 385 386 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
###xml 256 261 <span type="species:ncbi:10090">mouse</span>
###xml 317 322 <span type="species:ncbi:10090">mouse</span>
###xml 419 424 <span type="species:ncbi:10090">mouse</span>
Fluorogenic Assay Incubations-Assays were performed in a final volume of 150 mul using white 96-well plates and the following substrate and microsome concentrations: BFC, 50 mum substrate, 20 mug of mouse liver microsomes; EFC, 40 mum substrate, 15 mug of mouse liver microsomes; MFC, 180 mum of substrate, 15 mug of mouse liver microsomes; ethoxyresorufin (ER) and benzoxyresorufin (BR), 1 mum substrate, 11.25 mug of mouse liver microsomes. Reactions were measured in real time for 3 min, using the recommended excitation and emission wavelengths for each probe using a Fluroskan Ascent FL plate reading fluorimeter (Labsystems, UK). Turnover rates were calculated using authentic metabolite standards (7-hydroxy-4-trifluoromethylcoumarin for BFC, EFC, and MFC assays and resorufin for ER and BR assays).
###end p 22
###begin p 23
###xml 0 104 0 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NADH-mediated Incubations for HPLC or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis</italic>
###xml 207 208 206 207 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 323 324 320 321 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 441 442 435 436 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 559 560 550 551 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 679 680 667 668 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 799 800 784 785 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 242 247 <span type="species:ncbi:10090">mouse</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 478 483 <span type="species:ncbi:10090">mouse</span>
###xml 597 602 <span type="species:ncbi:10090">mouse</span>
###xml 717 722 <span type="species:ncbi:10090">mouse</span>
###xml 837 842 <span type="species:ncbi:10090">mouse</span>
NADH-mediated Incubations for HPLC or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis-NADH-mediated reactions were performed in triplicate using the following conditions: bufuralol, 300 mum (final concentration), 20 mug of mouse liver microsomes in a final volume of 150 mul for 6 min; chlorzoxazone, 1 mm (final concentration) and 20 mug of mouse liver microsomes in a final volume of 150 mul for 15 min; midazolam, 50 mum (final concentration) and 25 mugof mouse liver microsomes in a final volume of 150 mul for 9 min; metoprolol, 800 mum (final concentration) and 30 mug of mouse liver microsomes in a final volume of 150 mul for 60 min; phenacetin, 200 mum (final concentration) and 20 mug of mouse liver microsomes in a final volume of 100 mul for 9 min; tolbutamide, 800 mum (final concentration) and 30 mug of mouse liver microsomes in a final volume of 150 mul for 60 min. Assays were stopped by the addition of either 0.5 assay volumes (for bufuralol, chlorzoxazone, and tolbutamide assays) or 1 assay volume (for midazolam and phenacetin assays) of ice-cold methanol and incubated on ice for 10 min.
###end p 23
###begin p 24
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kinetic Determinations</italic>
###xml 345 346 344 345 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 370 371 368 369 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 393 394 390 391 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 418 419 414 415 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 444 445 439 440 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 759 769 754 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="disp-formula" rid="fd1">Equation 1</xref>
###xml 816 817 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 817 820 812 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 822 824 817 819 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 852 853 847 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Kinetic Determinations-Assays to determine the apparent kinetic parameters were performed in triplicate with wild-type and HBN liver microsomes under conditions of linearity for time and protein (data not shown) using the same buffer/NADPH conditions as described above, with the following concentrations of substrates: chlorzoxazone, 10-1000 mum; phenacetin, 1.7-150 mum; midazolam, 0.9-75 mum; metoprolol, 10-1000 mum; tolbutamide, 10-1000 mum (12 concentration points/determination). Metabolites were detected by LC-MS/MS as described in the supplemental materials. The data generated were analyzed by nonlinear regression using the Michaelis-Menten equation (chlorzoxazone, phenacetin, midazolam, and metoprolol), whereas the Hill equation (tolbutamide) (Equation 1) was used to determine the kinetic parameters Vmax,S50, and the Hill coefficient (n). 
###end p 24
###begin p 25
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vivo Pharmacokinetics</italic>
In Vivo Pharmacokinetics-Whole blood (10 mul) was taken from the tail vein at intervals after drug administration and transferred into a tube containing heparin (10 mul, 15 IU/ml). Internal standard solution (10 mul; 500 ng of caffeine and 500 ng of resorpine) was added to each tube. Protein precipitation was carried out by adding methanol (75 mul), followed by 8% sulfosalicylic acid (55 mul). Samples were mixed for 1 min and centrifuged at 13,000 rpm for 5 min, and the supernatant was analyzed by HPLC.
###end p 25
###begin p 26
The range of concentrations for the standard curves was constructed for quantifying blood levels by spiking blank blood samples with known amounts of chlorzoxazone, metoprolol, midazolam, phenacetin, and tolbutamide. Extraction and protein precipitation were carried out as outlined above for the test samples.
###end p 26
###begin p 27
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of in Vitro and in Vivo Data</italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 494 497 494 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
Analysis of in Vitro and in Vivo Data-Average rates of metabolism were calculated for each triplicate incubation of mouse liver microsomes from each genotype (n = 6), and these data were then used to calculate p values using an unpaired t test (available on the World Wide Web). Pharmacokinetic parameters were calculated using WinNonLin software, version 3.1. A simple noncompartmental model was used to calculate area under the curve (AUC), terminal half-life, maximum plasma concentration (Cmax), and clearance. Details of assays and separation conditions for HPLC and LC-MS/MS are given in the supplemental materials.
###end p 27
###begin title 28
RESULTS
###end title 28
###begin p 29
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hepatic Microsomal Cytochrome b<sub>5</sub> Null Mice</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 98 105 98 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 110 113 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>ALB</sup></italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 263 264 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 264 271 264 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 264 271 264 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 462 463 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 463 464 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 606 607 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 626 627 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 620 627 620 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 641 642 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 642 643 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 907 908 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 908 909 908 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1000 1001 1000 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1001 1002 1001 1002 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
###xml 43 47 <span type="species:ncbi:10090">Mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
Hepatic Microsomal Cytochrome b5 Null Mice-Mice nulled for hepatic microsomal cytochrome b5 (Cytb5lox/lox::CreALB) were born at the expected Mendelian ratio, developed normally, and displayed no overt phenotype when compared with their wild-type littermates (Cytb5lox/lox). Livers from adult HBN mice looked similar to those of wild-type animals, with no gross changes in general morphology or pathology noted. To establish whether hepatic microsomal cytochrome b5 protein had been deleted specifically, microsomes from liver, lung, kidney, and small and large intestine were immunoblotted for cytochrome b5 expression (Fig. 1A). Cytochrome b5 protein was virtually undetectable in microsomes from the livers of HBN mice; however, occasionally, a very faint band was observed in some samples, possibly originating from liver cells other than hepatocytes. There were no discernible differences in cytochrome b5 expression between the HBN and wild-type mice in the other organs examined. No cytochrome b5 protein could be detected in microsomes from the large intestine of either genotype (data not shown).
###end p 29
###begin p 30
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 229 236 229 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 482 489 482 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 589 590 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 984 985 972 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1011 1017 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 1045 1046 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
###xml 889 893 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
In order to investigate whether concomitant changes in P450 expression had occurred, three representative liver microsomal samples of each genotype were analyzed for P450 enzyme profiles, POR, and cytochrome b5 reductase levels (Fig. 1B). Although the expression of some P450s was slightly elevated in the HBN mice, these changes were not statistically significant. Cytochrome b5 reductase level was slightly increased when the immunoreactive bands were quantified by densitometry (Fig. 1C). A slight reduction in Cyp2d expression was also observed. As can be seen from supplemental Fig. 2A, there was no difference observed in the amount of spectrally active P450 in the HBN as compared with wild-type liver microsomes, with both samples containing approximately0.15 nmol of P450/mg of microsomal protein. POR protein levels were also essentially unchanged in HBN compared with wild-type mice, and although a slight increase in POR activity in HBN mice was measured using cytochrome c as substrate (228 +/- 65 versus 180 +/- 26 nmol cytochrome c reduced/min/mg), this change was not significant.
###end p 30
###begin p 31
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 74 75 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 9 94 9 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of protein expression in microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 230 234 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 234 235 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 235 242 234 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 235 242 234 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 247 250 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Alb</sup>
###xml 244 250 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>Alb</sup></italic>
###xml 265 266 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 266 273 265 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 261 273 260 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb<sub>5</sub><sup>lox/lox</sup></italic>
###xml 332 333 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 473 477 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 477 478 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 478 485 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 478 485 476 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 490 493 488 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Alb</sup>
###xml 487 493 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>Alb</sup></italic>
###xml 504 508 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 508 509 506 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 509 516 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 509 516 507 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 575 576 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 727 728 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 728 729 726 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 9 820 9 818 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><bold>Characterization of protein expression in microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold><italic>A</italic>, immunoblot analysis for cytochrome <italic>b</italic><sub>5</sub> expression in liver, kidney, lung, and small intestine microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb<sub>5</sub><sup>lox/lox</sup></italic> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, immunoblot analysis for expression of cytochrome P450-dependent monooxygenase components in liver microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>C</italic>, densitometric analysis of the liver microsome blots. Wild-type expression was fixed at 100%, and percentage difference was calculated for cytochrome <italic>b</italic><sub>5</sub> liver null (HBN) samples. Values were normalized for loading against Ponceau Red staining.</p>
###xml 9 820 9 818 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><bold>Characterization of protein expression in microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold><italic>A</italic>, immunoblot analysis for cytochrome <italic>b</italic><sub>5</sub> expression in liver, kidney, lung, and small intestine microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb<sub>5</sub><sup>lox/lox</sup></italic> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, immunoblot analysis for expression of cytochrome P450-dependent monooxygenase components in liver microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>C</italic>, densitometric analysis of the liver microsome blots. Wild-type expression was fixed at 100%, and percentage difference was calculated for cytochrome <italic>b</italic><sub>5</sub> liver null (HBN) samples. Values were normalized for loading against Ponceau Red staining.</p></caption>
###xml 820 820 818 818 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0500857170001"/>
###xml 0 820 0 818 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="32"><bold>Characterization of protein expression in microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold><italic>A</italic>, immunoblot analysis for cytochrome <italic>b</italic><sub>5</sub> expression in liver, kidney, lung, and small intestine microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb<sub>5</sub><sup>lox/lox</sup></italic> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, immunoblot analysis for expression of cytochrome P450-dependent monooxygenase components in liver microsomes (5 &#956;g of protein/lane) from <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup>::<italic>Cre<sup>Alb</sup></italic> (HBN) and <italic>Cytb</italic><sub>5</sub><sup><italic>lox/lox</italic></sup> (wild type), as detailed under &#8220;Experimental Procedures.&#8221; <italic>C</italic>, densitometric analysis of the liver microsome blots. Wild-type expression was fixed at 100%, and percentage difference was calculated for cytochrome <italic>b</italic><sub>5</sub> liver null (HBN) samples. Values were normalized for loading against Ponceau Red staining.</p></caption><graphic xlink:href="zbc0500857170001"/></fig>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
FIGURE 1.Characterization of protein expression in microsomal cytochrome b5 hepatic null mice.A, immunoblot analysis for cytochrome b5 expression in liver, kidney, lung, and small intestine microsomes (5 mug of protein/lane) from Cytb5lox/lox::CreAlb (HBN) and Cytb5lox/lox (wild type), as detailed under "Experimental Procedures." B, immunoblot analysis for expression of cytochrome P450-dependent monooxygenase components in liver microsomes (5 mug of protein/lane) from Cytb5lox/lox::CreAlb (HBN) and Cytb5lox/lox (wild type), as detailed under "Experimental Procedures." C, densitometric analysis of the liver microsome blots. Wild-type expression was fixed at 100%, and percentage difference was calculated for cytochrome b5 liver null (HBN) samples. Values were normalized for loading against Ponceau Red staining.
###end p 31
###begin p 32
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of protein expression in microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 221 225 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 225 226 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 226 233 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 226 233 225 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 238 241 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Alb</sup>
###xml 235 241 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>Alb</sup></italic>
###xml 256 257 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 257 264 256 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 252 264 251 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb<sub>5</sub><sup>lox/lox</sup></italic>
###xml 323 324 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 464 468 462 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 468 469 466 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 469 476 467 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 469 476 467 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 481 484 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Alb</sup>
###xml 478 484 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>Alb</sup></italic>
###xml 495 499 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 499 500 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 500 507 498 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 500 507 498 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 566 567 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 718 719 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 719 720 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Characterization of protein expression in microsomal cytochrome b5 hepatic null mice.A, immunoblot analysis for cytochrome b5 expression in liver, kidney, lung, and small intestine microsomes (5 mug of protein/lane) from Cytb5lox/lox::CreAlb (HBN) and Cytb5lox/lox (wild type), as detailed under "Experimental Procedures." B, immunoblot analysis for expression of cytochrome P450-dependent monooxygenase components in liver microsomes (5 mug of protein/lane) from Cytb5lox/lox::CreAlb (HBN) and Cytb5lox/lox (wild type), as detailed under "Experimental Procedures." C, densitometric analysis of the liver microsome blots. Wild-type expression was fixed at 100%, and percentage difference was calculated for cytochrome b5 liver null (HBN) samples. Values were normalized for loading against Ponceau Red staining.
###end p 32
###begin p 33
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 126 127 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 9 146 9 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold>
###xml 234 237 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 308 318 306 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Black bars</italic>
###xml 349 359 347 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 403 404 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 419 420 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 437 438 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 449 9 441 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><bold>NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold> Assays were performed in triplicate as described under &#8220;Experimental Procedures.&#8221; Each <italic>bar</italic> represents mean &#177; S.D. from six mouse liver microsome preparations. <italic>Black bars</italic> represent NADPH-mediated, and <italic>white bars</italic> NADH-mediated activities, respectively. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001.</p>
###xml 9 449 9 441 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34"><bold>NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold> Assays were performed in triplicate as described under &#8220;Experimental Procedures.&#8221; Each <italic>bar</italic> represents mean &#177; S.D. from six mouse liver microsome preparations. <italic>Black bars</italic> represent NADPH-mediated, and <italic>white bars</italic> NADH-mediated activities, respectively. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001.</p></caption>
###xml 449 449 441 441 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0500857170002"/>
###xml 0 449 0 441 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="34"><bold>NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold> Assays were performed in triplicate as described under &#8220;Experimental Procedures.&#8221; Each <italic>bar</italic> represents mean &#177; S.D. from six mouse liver microsome preparations. <italic>Black bars</italic> represent NADPH-mediated, and <italic>white bars</italic> NADH-mediated activities, respectively. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001.</p></caption><graphic xlink:href="zbc0500857170002"/></fig>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 272 277 <span type="species:ncbi:10090">mouse</span>
FIGURE 2.NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome b5 hepatic null mice. Assays were performed in triplicate as described under "Experimental Procedures." Each bar represents mean +/- S.D. from six mouse liver microsome preparations. Black bars represent NADPH-mediated, and white bars NADH-mediated activities, respectively. *, p </= 0.05; **, p </= 0.005; ***, p </= 0.001.
###end p 33
###begin p 34
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 0 137 0 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome <italic>b</italic><sub>5</sub> hepatic null mice.</bold>
###xml 225 228 225 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 299 309 297 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Black bars</italic>
###xml 340 350 338 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 394 395 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 410 411 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 428 429 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 263 268 <span type="species:ncbi:10090">mouse</span>
NADPH- and NADH-dependent cytochrome P450 activities in hepatic microsomes from wild-type and microsomal cytochrome b5 hepatic null mice. Assays were performed in triplicate as described under "Experimental Procedures." Each bar represents mean +/- S.D. from six mouse liver microsome preparations. Black bars represent NADPH-mediated, and white bars NADH-mediated activities, respectively. *, p </= 0.05; **, p </= 0.005; ***, p </= 0.001.
###end p 34
###begin p 35
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vitro Cytochrome P450 Activities</italic>
###xml 117 125 117 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 392 393 380 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 391 393 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 833 839 821 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 903 904 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 904 905 892 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1125 1126 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1126 1127 1114 1115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1140 1141 1128 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1141 1142 1129 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1215 1216 1203 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1221 1222 1209 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
In Vitro Cytochrome P450 Activities-Six commonly used P450 model substrates were used to establish if there were any in vitro differences in metabolism between liver microsomes from HBN and wild-type mice: BFC (CYP3A), MFC (CYP2C), EFC (CYP1A/2B), ER (CYP1A1/2, CYP1B1), BR (CYP2B/3A), and bufuralol (CYP2D) (30-36). Assays were performed at substrate concentrations of approximately5 times Km (mouse), as defined by the literature, or data were generated with recombinant mouse P450s (data not shown). With NADPH as electron donor, significantly lower turnover rates were measured in HBN mice relative to wild-type samples for all substrates tested. The NADPH-mediated rates in HBN liver microsomes, expressed relative to wild-type samples, were as follows: ER (73%), bufuralol (44%), BR (34%), BFC (19%), MFC (11%), and EFC (10%) (Fig. 2, supplemental Table 3). The addition of recombinant cytochrome b5 to HBN microsomes led to a concentration-dependent increase in BFC or chlorzoxazone metabolism, restoring activities to wild-type levels, demonstrating that the change in metabolism was due to the absence of cytochrome b5. Cytochrome b5 alone had no activity toward BFC or chlorzoxazone (supplemental Fig. 2, B and C).
###end p 35
###begin p 36
###xml 199 205 199 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 458 464 458 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
NADH could support monooxygenase activity for all model substrates in the wild-type samples, although the activity relative to NADPH was highly substrate-dependent, ranging from 4% (BR) to 74% (ER) (Fig. 2 and supplemental Table 3). All NADH-catalyzed reaction rates with the exception of BR were significantly lower in the HBN samples compared with wild type, with barely detectable activities using BFC (0.66%), EFC (0.79%), and MFC (0.28%) as substrates (Fig. 2 and supplemental Table 3). The metabolism of ER and bufuralol was also reduced, to 52 and 28% of wild-type values, respectively.
###end p 36
###begin p 37
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 814 815 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1046 1047 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1356 1357 1324 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
The NADH-mediated in vitro turnovers of the probe drugs chlorzoxazone (Cyp2e1), metoprolol (Cyp2d), midazolam (Cyp2c, Cyp3a), tolbutamide (Cyp2c), and phenacetin (Cyp1a) (37-41) were also examined with liver microsomes from both HBN and wild-type mice. NADH supported the metabolism of all substrates examined in wild-type liver microsomes, with the exception of tolbutamide. Rates observed were 601 +/- 152 (chlorzoxazone 6'-hydroxylation), 128 +/- 60 (metoprolol O-demethylation), 17.6 +/- 0.2 (metoprolol alpha-hydroxylation), 17.1 +/- 8.0 (midazolam 1'-hydroxylation), 9.1 +/- 3.8 (midazolam 4-hydroxylation), and 244 +/- 63 pmol/min/mg (phenacetin hydroxylation). These rates observed in wild-type liver microsomes were significantly lower than those observed using NADPH as co-factor, ranging from 7 to 29% (O-demethylmetoprolol and acetaminophen production, respectively) of the NADPH rate. Furthermore, the NADH-dependent turnover rates observed in HBN liver microsomes (177 +/- 64 (chlorzoxazone 6'-hydroxylation), 90 +/- 21 (metoprolol O-demethylation), 7.6 +/- 2.2 (metoprolol alpha-hydroxylation), 4.3 +/- 2.0 (midazolam 1'-hydroxylation), 2.1 +/- 2.7 (midazolam 4-hydroxylation), and 67 +/- 18 pmol/min/mg (phenacetin hydroxylation)) were significantly lower than the NADH-dependent wild-type rates (chlorzoxazone (29% reduction), metoprolol (O-demethyl 71%, alpha-hydroxy 44%, acid 83% reduction), midazolam (1'- and 4-hydroxy 25% reduction), and phenacetin (29% reduction)).
###end p 37
###begin p 38
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 9 148 9 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome <italic>b</italic><sub>5</sub> null mice.</bold>
###xml 364 377 364 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black circles</italic>
###xml 387 399 387 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 472 479 472 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 551 552 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 569 570 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 588 589 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 9 594 9 588 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39"><bold>Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome <italic>b</italic><sub>5</sub> null mice.</bold> A P450 drug mixture containing chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg) was administered intravenously at the indicated doses to wild-type (<italic>black circles</italic>) or HBN (<italic>open circles</italic>) mice, and blood samples were taken at timed intervals to determine the <italic>in vivo</italic> pharmacokinetic parameters of the parent compounds. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001, where <italic>n</italic> = 5.</p>
###xml 9 594 9 588 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39"><bold>Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome <italic>b</italic><sub>5</sub> null mice.</bold> A P450 drug mixture containing chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg) was administered intravenously at the indicated doses to wild-type (<italic>black circles</italic>) or HBN (<italic>open circles</italic>) mice, and blood samples were taken at timed intervals to determine the <italic>in vivo</italic> pharmacokinetic parameters of the parent compounds. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001, where <italic>n</italic> = 5.</p></caption>
###xml 594 594 588 588 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0500857170003"/>
###xml 0 594 0 588 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="39"><bold>Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome <italic>b</italic><sub>5</sub> null mice.</bold> A P450 drug mixture containing chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg) was administered intravenously at the indicated doses to wild-type (<italic>black circles</italic>) or HBN (<italic>open circles</italic>) mice, and blood samples were taken at timed intervals to determine the <italic>in vivo</italic> pharmacokinetic parameters of the parent compounds. *, <italic>p</italic> &#8804; 0.05; **, <italic>p</italic> &#8804; 0.005; ***, <italic>p</italic> &#8804; 0.001, where <italic>n</italic> = 5.</p></caption><graphic xlink:href="zbc0500857170003"/></fig>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
FIGURE 3.Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome b5 null mice. A P450 drug mixture containing chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg) was administered intravenously at the indicated doses to wild-type (black circles) or HBN (open circles) mice, and blood samples were taken at timed intervals to determine the in vivo pharmacokinetic parameters of the parent compounds. *, p </= 0.05; **, p </= 0.005; ***, p </= 0.001, where n = 5.
###end p 38
###begin p 39
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 0 139 0 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome <italic>b</italic><sub>5</sub> null mice.</bold>
###xml 355 368 355 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black circles</italic>
###xml 378 390 378 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 463 470 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 526 527 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 542 543 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 560 561 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 579 580 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
Pharmacokinetic disposition of an intravenously administered P450 drug mixture in wild-type and hepatic microsomal cytochrome b5 null mice. A P450 drug mixture containing chlorzoxazone (5 mg/kg), metoprolol (2 mg/kg), midazolam (5 mg/kg), phenacetin (5 mg/kg), and tolbutamide (5 mg/kg) was administered intravenously at the indicated doses to wild-type (black circles) or HBN (open circles) mice, and blood samples were taken at timed intervals to determine the in vivo pharmacokinetic parameters of the parent compounds. *, p </= 0.05; **, p </= 0.005; ***, p </= 0.001, where n = 5.
###end p 39
###begin p 40
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vitro Kinetics</italic>
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 473 474 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 474 475 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 514 515 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 515 518 511 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 701 702 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 750 751 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 751 754 743 746 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 828 829 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 827 829 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 920 921 912 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 919 921 911 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 980 981 972 973 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 979 981 971 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 997 998 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 1239 1240 1231 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1238 1240 1230 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 1290 1291 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 1291 1294 1283 1286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1390 1396 1382 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 1501 1502 1493 1494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1500 1502 1492 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 1505 1506 1497 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 1506 1509 1498 1501 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1590 1592 1582 1584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m1</sub>
###xml 1589 1592 1581 1584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m1</sub></italic>
In Vitro Kinetics-The apparent kinetic parameters of the probe drugs using NADPH as co-factor were determined in wild-type and HBN liver microsomes, and metabolism of chlorzoxazone, phenacetin, midazolam, and metoprolol followed standard Michaelis-Menten kinetics (Table 1). The Michaelis constant for chlorzoxazone 6-hydroxylation, midazolam 1'-hydroxylation, phenacetin oxidation, and metoprolol alpha-hydroxylation were unchanged by the removal of microsomal cytochrome b5. Conversely, for those reactions, the Vmax was markedly reduced in the HBN samples, ranging from a 2-fold (phenacetin oxidation) to a 6-fold (metoprolol alpha-hydroxylation) decrease. Midazolam 4-hydroxylation and metoprolol O-demethylation reactions again showed decreased Vmax values for the HBN samples (20- and 3-fold, respectively); however, the Km values were marginally affected, with the HBN samples exhibiting a 1.7-fold reduction in Km for midazolam 4-hydroxylation and a 1.8-fold increase in Km for metoprolol O-demethylation as compared with wild type. The data obtained for tolbutamide hydroxylation could not be fitted using the Michaelis-Menten equation but did conform to the Hill equation. Interestingly, the HBN sample exhibited 68-fold higher Km for tolbutamide as well as a 5-fold reduction in Vmax as compared with wild type. The Hill coefficient for both wild type and HBN were similar (0.38 versus 0.29) and indicative of tolbutamide binding in a negatively cooperative manner. The alternative of a 2 Km,2 Vmax fit was considered for these data; however, when plotted in such a manner, the Km1 parameter for both wild type and HBN was subject to such a large error as to render it meaningless.
###end p 40
###begin p 41
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 115 7 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls</bold>
###xml 7 115 7 115 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls</bold></p>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 115 501 115 501 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">Assays were performed in triplicate for each concentration of substrate. S.D. values given are from the fit of the curve as calculated using the Michaelis-Menten equation (GraFit version 5 (Erithacus Software, Horley, UK)). For tolbutamide, the Hill equation (GraFit version 5) was used to fit the data, giving Hill coefficients (<italic>n</italic>) of 0.38 and 0.29 for wild type and HBN, respectively.</p>
###xml 7 501 7 501 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls</bold></p><p textid="43">Assays were performed in triplicate for each concentration of substrate. S.D. values given are from the fit of the curve as calculated using the Michaelis-Menten equation (GraFit version 5 (Erithacus Software, Horley, UK)). For tolbutamide, the Hill equation (GraFit version 5) was used to fit the data, giving Hill coefficients (<italic>n</italic>) of 0.38 and 0.29 for wild type and HBN, respectively.</p></caption>
###xml 501 510 501 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Substrate</bold>
###xml 510 510 510 510 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 501 510 501 510 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="2" align="center" valign="bottom"><bold>Substrate</bold><hr/></th>
###xml 510 520 510 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Metabolite</bold>
###xml 520 520 520 520 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 510 520 510 520 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="2" align="center" valign="bottom"><bold>Metabolite</bold><hr/></th>
###xml 520 529 520 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Wild type</bold>
###xml 529 529 529 529 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 520 529 520 529 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2" rowspan="1" align="center" valign="bottom"><bold>Wild type</bold><hr/></th>
###xml 529 532 529 532 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HBN</bold>
###xml 532 532 532 532 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 529 532 529 532 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2" rowspan="1" align="center" valign="bottom"><bold>HBN</bold><hr/></th>
###xml 501 532 501 532 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Substrate</bold><hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Metabolite</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Wild type</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>HBN</bold><hr/></th></tr>
###xml 533 534 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 532 534 532 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 532 534 532 534 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>K<sub>m</sub></italic></bold>
###xml 532 534 532 534 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th>
###xml 534 535 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 535 538 535 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 534 538 534 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>V</italic><sub>max</sub></bold>
###xml 534 538 534 538 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th>
###xml 539 540 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 538 540 538 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 538 540 538 540 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>K<sub>m</sub></italic></bold>
###xml 538 540 538 540 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 541 544 541 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 540 544 540 544 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>V</italic><sub>max</sub></bold>
###xml 540 544 540 544 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th>
###xml 532 544 532 544 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th></tr>
###xml 501 544 501 544 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Substrate</bold><hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Metabolite</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Wild type</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>HBN</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th></tr></thead>
###xml 544 544 544 544 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 544 544 544 544 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 547 548 546 547 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 547 548 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sc>m</sc></italic>
###xml 544 548 544 547 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td>
###xml 548 559 547 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pmol/min/mg</italic>
###xml 548 559 547 558 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td>
###xml 562 563 560 561 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 562 563 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sc>m</sc></italic>
###xml 559 563 558 561 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td>
###xml 563 574 561 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pmol/min/mg</italic>
###xml 563 574 561 572 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td>
###xml 544 574 544 572 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td></tr>
###xml 574 589 572 587 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td>
###xml 589 613 587 611 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 6-Hydroxychlorzoxazone </td>
###xml 613 623 611 619 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 47 &#177; 9 </td>
###xml 623 637 619 631 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1930 &#177; 100 </td>
###xml 637 647 631 639 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 53 &#177; 6 </td>
###xml 647 659 639 649 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 387 &#177; 11 </td>
###xml 574 659 572 649 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 6-Hydroxychlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 47 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1930 &#177; 100 </td><td colspan="1" rowspan="1" align="center" valign="top"> 53 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 387 &#177; 11 </td></tr>
###xml 659 670 649 660 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td>
###xml 670 691 660 681 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1&#8242;-Hydroxymidazolam </td>
###xml 691 704 681 692 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#177; 0.3 </td>
###xml 704 716 692 702 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 389 &#177; 15 </td>
###xml 716 729 702 713 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.0 &#177; 0.3 </td>
###xml 729 740 713 722 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 116 &#177; 4 </td>
###xml 659 740 649 722 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 1&#8242;-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 389 &#177; 15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.0 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 116 &#177; 4 </td></tr>
###xml 740 751 722 733 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td>
###xml 751 771 733 753 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 4-Hydroxymidazolam </td>
###xml 771 785 753 765 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 13.3 &#177; 0.4 </td>
###xml 785 796 765 774 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 146 &#177; 2 </td>
###xml 796 809 774 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 7.7 &#177; 0.9 </td>
###xml 809 822 785 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 7.3 &#177; 0.3 </td>
###xml 740 822 722 796 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 4-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 146 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.7 &#177; 0.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.3 &#177; 0.3 </td></tr>
###xml 822 834 796 808 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td>
###xml 834 849 808 823 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> Acetaminophen </td>
###xml 849 862 823 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 5.6 &#177; 1.0 </td>
###xml 862 873 834 843 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 133 &#177; 6 </td>
###xml 873 886 843 854 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 4.1 &#177; 0.7 </td>
###xml 886 896 854 862 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 77 &#177; 3 </td>
###xml 822 896 796 862 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="center" valign="top"> Acetaminophen </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.6 &#177; 1.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 133 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.1 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 77 &#177; 3 </td></tr>
###xml 896 908 862 874 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td>
###xml 908 933 874 895 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#945;-Hydroxymetoprolol </td>
###xml 933 943 895 903 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 84 &#177; 7 </td>
###xml 943 955 903 913 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 483 &#177; 14 </td>
###xml 955 965 913 921 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 99 &#177; 9 </td>
###xml 965 975 921 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 76 &#177; 3 </td>
###xml 896 975 862 929 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> &#945;-Hydroxymetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 84 &#177; 7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 483 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 99 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 76 &#177; 3 </td></tr>
###xml 975 987 929 941 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td>
###xml 987 988 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 987 1009 941 963 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>O</italic>-Desmethylmetoprolol </td>
###xml 1009 1019 963 971 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 86 &#177; 9 </td>
###xml 1019 1031 971 981 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1650 &#177; 2 </td>
###xml 1031 1043 981 991 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 157 &#177; 14 </td>
###xml 1043 1055 991 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 531 &#177; 21 </td>
###xml 975 1055 929 1001 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"><italic>O</italic>-Desmethylmetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 86 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1650 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 157 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 531 &#177; 21 </td></tr>
###xml 1055 1068 1001 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td>
###xml 1068 1088 1014 1034 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> Hydroxytolbutamide </td>
###xml 1088 1104 1034 1048 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 11200 &#177; 3400 </td>
###xml 1104 1116 1048 1058 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 211 &#177; 17 </td>
###xml 1116 1128 1058 1068 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 165 &#177; 48 </td>
###xml 1128 1140 1068 1078 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 44 &#177; 165 </td>
###xml 1055 1140 1001 1078 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> Hydroxytolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> 11200 &#177; 3400 </td><td colspan="1" rowspan="1" align="center" valign="top"> 211 &#177; 17 </td><td colspan="1" rowspan="1" align="center" valign="top"> 165 &#177; 48 </td><td colspan="1" rowspan="1" align="center" valign="top"> 44 &#177; 165 </td></tr>
###xml 544 1140 544 1078 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 6-Hydroxychlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 47 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1930 &#177; 100 </td><td colspan="1" rowspan="1" align="center" valign="top"> 53 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 387 &#177; 11 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 1&#8242;-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 389 &#177; 15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.0 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 116 &#177; 4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 4-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 146 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.7 &#177; 0.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.3 &#177; 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="center" valign="top"> Acetaminophen </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.6 &#177; 1.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 133 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.1 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 77 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> &#945;-Hydroxymetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 84 &#177; 7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 483 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 99 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 76 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"><italic>O</italic>-Desmethylmetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 86 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1650 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 157 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 531 &#177; 21 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> Hydroxytolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> 11200 &#177; 3400 </td><td colspan="1" rowspan="1" align="center" valign="top"> 211 &#177; 17 </td><td colspan="1" rowspan="1" align="center" valign="top"> 165 &#177; 48 </td><td colspan="1" rowspan="1" align="center" valign="top"> 44 &#177; 165 </td></tr></tbody>
###xml 501 1140 501 1078 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Substrate</bold><hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Metabolite</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Wild type</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>HBN</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 6-Hydroxychlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 47 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1930 &#177; 100 </td><td colspan="1" rowspan="1" align="center" valign="top"> 53 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 387 &#177; 11 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 1&#8242;-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 389 &#177; 15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.0 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 116 &#177; 4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 4-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 146 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.7 &#177; 0.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.3 &#177; 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="center" valign="top"> Acetaminophen </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.6 &#177; 1.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 133 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.1 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 77 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> &#945;-Hydroxymetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 84 &#177; 7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 483 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 99 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 76 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"><italic>O</italic>-Desmethylmetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 86 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1650 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 157 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 531 &#177; 21 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> Hydroxytolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> 11200 &#177; 3400 </td><td colspan="1" rowspan="1" align="center" valign="top"> 211 &#177; 17 </td><td colspan="1" rowspan="1" align="center" valign="top"> 165 &#177; 48 </td><td colspan="1" rowspan="1" align="center" valign="top"> 44 &#177; 165 </td></tr></tbody></table>
###xml 0 1140 0 1078 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="42"><bold>Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls</bold></p><p textid="43">Assays were performed in triplicate for each concentration of substrate. S.D. values given are from the fit of the curve as calculated using the Michaelis-Menten equation (GraFit version 5 (Erithacus Software, Horley, UK)). For tolbutamide, the Hill equation (GraFit version 5) was used to fit the data, giving Hill coefficients (<italic>n</italic>) of 0.38 and 0.29 for wild type and HBN, respectively.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Substrate</bold><hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Metabolite</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Wild type</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>HBN</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>V</italic><sub>max</sub></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>pmol/min/mg</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 6-Hydroxychlorzoxazone </td><td colspan="1" rowspan="1" align="center" valign="top"> 47 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1930 &#177; 100 </td><td colspan="1" rowspan="1" align="center" valign="top"> 53 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 387 &#177; 11 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 1&#8242;-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 389 &#177; 15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.0 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 116 &#177; 4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 4-Hydroxymidazolam </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 146 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.7 &#177; 0.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.3 &#177; 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="center" valign="top"> Acetaminophen </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.6 &#177; 1.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 133 &#177; 6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.1 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 77 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> &#945;-Hydroxymetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 84 &#177; 7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 483 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 99 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 76 &#177; 3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"><italic>O</italic>-Desmethylmetoprolol </td><td colspan="1" rowspan="1" align="center" valign="top"> 86 &#177; 9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1650 &#177; 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 157 &#177; 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 531 &#177; 21 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> Hydroxytolbutamide </td><td colspan="1" rowspan="1" align="center" valign="top"> 11200 &#177; 3400 </td><td colspan="1" rowspan="1" align="center" valign="top"> 211 &#177; 17 </td><td colspan="1" rowspan="1" align="center" valign="top"> 165 &#177; 48 </td><td colspan="1" rowspan="1" align="center" valign="top"> 44 &#177; 165 </td></tr></tbody></table></table-wrap>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
TABLE 1Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controlsAssays were performed in triplicate for each concentration of substrate. S.D. values given are from the fit of the curve as calculated using the Michaelis-Menten equation (GraFit version 5 (Erithacus Software, Horley, UK)). For tolbutamide, the Hill equation (GraFit version 5) was used to fit the data, giving Hill coefficients (n) of 0.38 and 0.29 for wild type and HBN, respectively.SubstrateMetaboliteWild typeHBNKmVmaxKmVmax mumpmol/min/mg mumpmol/min/mg Chlorzoxazone  6-Hydroxychlorzoxazone  47 +/- 9  1930 +/- 100  53 +/- 6  387 +/- 11  Midazolam  1'-Hydroxymidazolam  2.1 +/- 0.3  389 +/- 15  2.0 +/- 0.3  116 +/- 4  Midazolam  4-Hydroxymidazolam  13.3 +/- 0.4  146 +/- 2  7.7 +/- 0.9  7.3 +/- 0.3  Phenacetin  Acetaminophen  5.6 +/- 1.0  133 +/- 6  4.1 +/- 0.7  77 +/- 3  Metoprolol  alpha-Hydroxymetoprolol  84 +/- 7  483 +/- 14  99 +/- 9  76 +/- 3  Metoprolol O-Desmethylmetoprolol  86 +/- 9  1650 +/- 2  157 +/- 14  531 +/- 21  Tolbutamide  Hydroxytolbutamide  11200 +/- 3400  211 +/- 17  165 +/- 48  44 +/- 165 
###end p 41
###begin p 42
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls</bold>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Kinetic analyses of the metabolism of probe drugs by hepatic microsomes from HBN mice and wild-type controls
###end p 42
###begin p 43
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Assays were performed in triplicate for each concentration of substrate. S.D. values given are from the fit of the curve as calculated using the Michaelis-Menten equation (GraFit version 5 (Erithacus Software, Horley, UK)). For tolbutamide, the Hill equation (GraFit version 5) was used to fit the data, giving Hill coefficients (n) of 0.38 and 0.29 for wild type and HBN, respectively.
###end p 43
###begin p 44
###xml 252 256 <span type="species:ncbi:10090">mice</span>
To ensure that the observed changes in P450 activity were not a consequence of perturbations of the phospholipid bilayer, fatty acid profile analysis was carried out on endoplasmic reticulum membrane fractions from the livers of both wild type and HBN mice. No significant changes in the levels of fatty acids were observed. In addition, hepatic lipid levels were unchanged, as determined by Oil Red O staining (supplemental Fig. 3).
###end p 44
###begin p 45
###xml 0 65 0 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vivo Pharmacokinetics of Probe Drugs in Wild-type and HBN Mice</italic>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 156 163 156 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 923 929 923 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 61 65 <span type="species:ncbi:10090">Mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
In Vivo Pharmacokinetics of Probe Drugs in Wild-type and HBN Mice-We next investigated the effect of the absence of hepatic microsomal cytochrome b5 on the in vivo pharmacokinetics of the probe drugs in wild-type and HBN mice. Initially, mice were administered chlorzoxazone, metoprolol, midazolam, tolbutamide, and phenacetin either as an intravenous or oral mixture. Previous work with these drugs in wild-type mice, individually and as a mixture, had demonstrated that simultaneous delivery did not result in altered pharmacokinetics as compared with single administration (not shown). Following dosing of the drug cassette to wild-type and HBN mice, quantification of individual drugs and their metabolites was carried out by LC-MS/MS. The complete set of pharmacokinetic parameters for each drug is summarized in supplemental Tables 4 (intravenous) and 5 (oral), and the elimination profiles of the drugs are shown in Fig. 3 (intravenous) and supplemental Fig. 4 (oral).
###end p 45
###begin p 46
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Intravenous Pharmacokinetics</italic>
###xml 934 941 934 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 943 949 943 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1117 1118 1117 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 833 837 <span type="species:ncbi:10090">mice</span>
###xml 1066 1070 <span type="species:ncbi:10090">mice</span>
Intravenous Pharmacokinetics-Following intravenous administration of the drug mixture, wild-type mice showed a higher concentration of parent drug in the blood at the early time points (0-60 min) compared with the HBN mice for all drugs in the mixture. In contrast, from 2 h, the average concentration of parent drug was statistically much lower in the wild-type than in HBN mice for most of the compounds and remained so for the duration of the experiment. Pharmacokinetic analysis for each drug showed that the clearance was consistently faster, and the AUC was consistently lower (except in the case of midazolam) in wild-type compared with HBN mice. Furthermore, the terminal half-life for phenacetin, tolbutamide, chlorzoxazone, and midazolam was statistically different between the two lines, being significantly longer in HBN mice, increasing from 53 to 168 min, 197 to 321 min, 92 to 257 min, and 83 to 329 min, respectively (Table 2, Fig. 3, and supplemental Table 4). For metoprolol, although a 2.7-fold increase of the terminal half-life was found in HBN mice, this did not reach statistical significance (p = 0.1).
###end p 46
###begin p 47
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 2</label>
###xml 7 14 7 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 7 98 7 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vivo</italic> pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture</bold>
###xml 7 98 7 98 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><bold><italic>In vivo</italic> pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture</bold></p>
###xml 98 482 98 464 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Adult male HBN and WT mice were administered a drug mixture intravenously; serial blood samples were collected over an 8-h period and analyzed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. Absolute oral bioavailability was calculated by dividing AUC (0 &#8594; &#8734;, oral) by AUC (0 &#8594; &#8734;, intravenous) (supplemental Tables 4 and 5).</p>
###xml 7 482 7 464 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48"><bold><italic>In vivo</italic> pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture</bold></p><p textid="49">Adult male HBN and WT mice were administered a drug mixture intravenously; serial blood samples were collected over an 8-h period and analyzed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. Absolute oral bioavailability was calculated by dividing AUC (0 &#8594; &#8734;, oral) by AUC (0 &#8594; &#8734;, intravenous) (supplemental Tables 4 and 5).</p></caption>
###xml 482 486 464 468 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Drug</bold>
###xml 486 486 468 468 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 482 486 464 468 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="2" align="center" valign="bottom"><bold>Drug</bold><hr/></th>
###xml 486 518 468 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Terminal half-life (intravenous)</bold>
###xml 518 518 500 500 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 486 518 468 500 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2" rowspan="1" align="center" valign="bottom"><bold>Terminal half-life (intravenous)</bold><hr/></th>
###xml 518 537 500 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Bioavailability (%)</bold>
###xml 537 537 519 519 <hr xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 518 537 500 519 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2" rowspan="1" align="center" valign="bottom"><bold>Bioavailability (%)</bold><hr/></th>
###xml 482 537 464 519 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Drug</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Terminal half-life (intravenous)</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Bioavailability (%)</bold><hr/></th></tr>
###xml 537 546 519 528 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Wild type</bold>
###xml 537 546 519 528 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th>
###xml 546 549 528 531 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HBN</bold>
###xml 546 549 528 531 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th>
###xml 549 558 531 540 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Wild type</bold>
###xml 549 558 531 540 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th>
###xml 558 561 540 543 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HBN</bold>
###xml 558 561 540 543 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th>
###xml 537 561 519 543 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th></tr>
###xml 482 561 464 543 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Drug</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Terminal half-life (intravenous)</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Bioavailability (%)</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th></tr></thead>
###xml 561 572 543 554 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td>
###xml 572 583 554 563 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 83 &#177; 15 </td>
###xml 583 596 563 574 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> 329 &#177; 132 </td>
###xml 596 600 574 578 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 14 </td>
###xml 600 604 578 582 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 55 </td>
###xml 561 604 543 582 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="right" valign="top"> 83 &#177; 15 </td><td colspan="1" rowspan="1" align="left" valign="top"> 329 &#177; 132 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 55 </td></tr>
###xml 604 616 582 594 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td>
###xml 616 627 594 603 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 53 &#177; 11 </td>
###xml 627 639 603 613 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> 168 &#177; 56 </td>
###xml 639 644 613 618 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.6 </td>
###xml 644 649 618 623 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.8 </td>
###xml 604 649 582 623 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="right" valign="top"> 53 &#177; 11 </td><td colspan="1" rowspan="1" align="left" valign="top"> 168 &#177; 56 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.8 </td></tr>
###xml 649 661 623 635 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td>
###xml 661 672 635 644 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 96 &#177; 13 </td>
###xml 672 684 644 654 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> 260 &#177; 65 </td>
###xml 684 689 654 659 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td>
###xml 689 694 659 664 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td>
###xml 649 694 623 664 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="right" valign="top"> 96 &#177; 13 </td><td colspan="1" rowspan="1" align="left" valign="top"> 260 &#177; 65 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td></tr>
###xml 694 709 664 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td>
###xml 709 720 679 688 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 92 &#177; 19 </td>
###xml 720 732 688 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> 257 &#177; 76 </td>
###xml 732 737 698 703 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 3.7 </td>
###xml 737 742 703 708 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.9 </td>
###xml 694 742 664 708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="right" valign="top"> 92 &#177; 19 </td><td colspan="1" rowspan="1" align="left" valign="top"> 257 &#177; 76 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.9 </td></tr>
###xml 742 755 708 721 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td>
###xml 755 767 721 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 197 &#177; 37 </td>
###xml 767 779 731 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> 321 &#177; 25 </td>
###xml 788 789 750 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 788 789 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 779 789 741 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 95 (154)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td>
###xml 798 799 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 798 799 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 789 799 751 761 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 47 (135)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td>
###xml 742 799 708 761 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="right" valign="top"> 197 &#177; 37 </td><td colspan="1" rowspan="1" align="left" valign="top"> 321 &#177; 25 </td><td colspan="1" rowspan="1" align="center" valign="top"> 95 (154)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td><td colspan="1" rowspan="1" align="center" valign="top"> 47 (135)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td></tr>
###xml 561 799 543 761 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="right" valign="top"> 83 &#177; 15 </td><td colspan="1" rowspan="1" align="left" valign="top"> 329 &#177; 132 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 55 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="right" valign="top"> 53 &#177; 11 </td><td colspan="1" rowspan="1" align="left" valign="top"> 168 &#177; 56 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="right" valign="top"> 96 &#177; 13 </td><td colspan="1" rowspan="1" align="left" valign="top"> 260 &#177; 65 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="right" valign="top"> 92 &#177; 19 </td><td colspan="1" rowspan="1" align="left" valign="top"> 257 &#177; 76 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="right" valign="top"> 197 &#177; 37 </td><td colspan="1" rowspan="1" align="left" valign="top"> 321 &#177; 25 </td><td colspan="1" rowspan="1" align="center" valign="top"> 95 (154)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td><td colspan="1" rowspan="1" align="center" valign="top"> 47 (135)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td></tr></tbody>
###xml 482 799 464 761 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Drug</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Terminal half-life (intravenous)</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Bioavailability (%)</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="right" valign="top"> 83 &#177; 15 </td><td colspan="1" rowspan="1" align="left" valign="top"> 329 &#177; 132 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 55 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="right" valign="top"> 53 &#177; 11 </td><td colspan="1" rowspan="1" align="left" valign="top"> 168 &#177; 56 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="right" valign="top"> 96 &#177; 13 </td><td colspan="1" rowspan="1" align="left" valign="top"> 260 &#177; 65 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="right" valign="top"> 92 &#177; 19 </td><td colspan="1" rowspan="1" align="left" valign="top"> 257 &#177; 76 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="right" valign="top"> 197 &#177; 37 </td><td colspan="1" rowspan="1" align="left" valign="top"> 321 &#177; 25 </td><td colspan="1" rowspan="1" align="center" valign="top"> 95 (154)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td><td colspan="1" rowspan="1" align="center" valign="top"> 47 (135)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td></tr></tbody></table>
###xml 799 800 761 762 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 800 863 762 825 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">Comparative data where tolbutamide was dosed as a single agent.</p>
###xml 799 863 761 825 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn1"><label>a</label><p textid="50">Comparative data where tolbutamide was dosed as a single agent.</p></fn>
###xml 799 863 761 825 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn1"><label>a</label><p textid="50">Comparative data where tolbutamide was dosed as a single agent.</p></fn></table-wrap-foot>
###xml 0 863 0 825 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl2"><label>TABLE 2</label><caption><p textid="48"><bold><italic>In vivo</italic> pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture</bold></p><p textid="49">Adult male HBN and WT mice were administered a drug mixture intravenously; serial blood samples were collected over an 8-h period and analyzed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. Absolute oral bioavailability was calculated by dividing AUC (0 &#8594; &#8734;, oral) by AUC (0 &#8594; &#8734;, intravenous) (supplemental Tables 4 and 5).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom"><bold>Drug</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Terminal half-life (intravenous)</bold><hr/></th><th colspan="2" rowspan="1" align="center" valign="bottom"><bold>Bioavailability (%)</bold><hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Wild type</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>HBN</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Midazolam </td><td colspan="1" rowspan="1" align="right" valign="top"> 83 &#177; 15 </td><td colspan="1" rowspan="1" align="left" valign="top"> 329 &#177; 132 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14 </td><td colspan="1" rowspan="1" align="center" valign="top"> 55 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Phenacetin </td><td colspan="1" rowspan="1" align="right" valign="top"> 53 &#177; 11 </td><td colspan="1" rowspan="1" align="left" valign="top"> 168 &#177; 56 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Metoprolol </td><td colspan="1" rowspan="1" align="right" valign="top"> 96 &#177; 13 </td><td colspan="1" rowspan="1" align="left" valign="top"> 260 &#177; 65 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.3 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chlorzoxazone </td><td colspan="1" rowspan="1" align="right" valign="top"> 92 &#177; 19 </td><td colspan="1" rowspan="1" align="left" valign="top"> 257 &#177; 76 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tolbutamide </td><td colspan="1" rowspan="1" align="right" valign="top"> 197 &#177; 37 </td><td colspan="1" rowspan="1" align="left" valign="top"> 321 &#177; 25 </td><td colspan="1" rowspan="1" align="center" valign="top"> 95 (154)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td><td colspan="1" rowspan="1" align="center" valign="top"> 47 (135)<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p textid="50">Comparative data where tolbutamide was dosed as a single agent.</p></fn></table-wrap-foot></table-wrap>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
TABLE 2In vivo pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixtureAdult male HBN and WT mice were administered a drug mixture intravenously; serial blood samples were collected over an 8-h period and analyzed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. Absolute oral bioavailability was calculated by dividing AUC (0 --> infinity, oral) by AUC (0 --> infinity, intravenous) (supplemental Tables 4 and 5).DrugTerminal half-life (intravenous)Bioavailability (%)Wild typeHBNWild typeHBN Midazolam  83 +/- 15  329 +/- 132  14  55  Phenacetin  53 +/- 11  168 +/- 56  0.6  0.8  Metoprolol  96 +/- 13  260 +/- 65  0.3  0.3  Chlorzoxazone  92 +/- 19  257 +/- 76  3.7  1.9  Tolbutamide  197 +/- 37  321 +/- 25  95 (154)a 47 (135)aaComparative data where tolbutamide was dosed as a single agent.
###end p 47
###begin p 48
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vivo</italic> pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture</bold>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
In vivo pharmacokinetic data from HBN mice and wild-type controls dosed with a drug mixture
###end p 48
###begin p 49
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Adult male HBN and WT mice were administered a drug mixture intravenously; serial blood samples were collected over an 8-h period and analyzed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. Absolute oral bioavailability was calculated by dividing AUC (0 --> infinity, oral) by AUC (0 --> infinity, intravenous) (supplemental Tables 4 and 5).
###end p 49
###begin p 50
Comparative data where tolbutamide was dosed as a single agent.
###end p 50
###begin p 51
###xml 37 38 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 423 429 423 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 453 454 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
The major metabolites of metoprolol (O-demethylmetoprolol), phenacetin (acetaminophen), and midazolam (1-OH midazolam) were also measured in the serum of HBN and wild-type mice after intravenous administration; the results are presented in supplemental Fig. 5A. Interestingly, the overall profiles of metabolite production in HBN mice were shifted to the right, consistent with a delayed metabolism of the parent compound (Fig. 3 and supplemental Fig. 5A). Tolbutamide and chlorzoxazone metabolites were below the limit of detection at all time points.
###end p 51
###begin p 52
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oral Pharmacokinetics</italic>
###xml 242 245 242 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 386 389 386 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 642 645 640 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 900 903 896 899 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1107 1110 1103 1106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1483 1486 1479 1482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 1433 1437 <span type="species:ncbi:10090">mice</span>
###xml 1518 1522 <span type="species:ncbi:10090">mice</span>
###xml 1658 1662 <span type="species:ncbi:10090">mice</span>
Oral Pharmacokinetics-Following oral administration of the drug mixture, differences in the elimination profiles of all of the drugs were observed between wild-type and HBN mice. In the case of midazolam, phenacetin, and metoprolol, AUC and Cmax were consistently higher in HBN mice, whereas the clearance was slower (supplemental Fig. 4, supplemental Table 5). For midazolam, AUC and Cmax were significantly increased from 34 to 124 min.mug/ml and from 0.4 to 1.0 mug/ml, respectively, whereas clearance was decreased from 149 to 41 ml/min/kg (supplemental Table 5). The phenacetin elimination profile also showed significant changes, with Cmax increasing from 0.06 to 0.09 mug/ml in HBN and clearance decreasing from 688 to 550 ml/min/kg. Although the phenacetin AUC increased from 1.5 to 1.8 min.mug/ml, this change was not significant. In the case of metoprolol, similar trends were observed in Cmax and AUC; however, these did not reach statistical significance. In contrast to the observations above, the alterations in the pharmacokinetic parameters for tolbutamide gave significantly lower AUC and Cmax values and a (nonsignificant) higher clearance rate, relative to wild-type animals (supplemental Fig. 4 and supplemental Table 5). This unexpected effect appeared to be a consequence of using the drug mixture (see below). Interestingly, although the terminal half-life for chlorzoxazone was significantly decreased in HBN mice from 194.0 to 46 min, the decreased AUC and Cmax and increased clearance in HBN mice were not significantly different (supplemental Table 5). Additionally, there were no significant differences between HBN and wild-type mice in the plasma concentration of chlorzoxazone at any of the time points analyzed (supplemental Fig. 4).
###end p 52
###begin p 53
###xml 327 335 327 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A, inset</italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 483 486 483 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
Administration of the probe drugs individually to HBN and wild-type mice yielded essentially the same elimination profiles for phenacetin, metoprolol, midazolam, and chlorzoxazone, compared with those obtained from use of the drug mixture (data not shown). However, when tolbutamide was administered singly (supplemental Fig. 4A, inset), the elimination profiles were found to be reversed in comparison with that obtained from the drug mixture (i.e. significantly increased AUC and Cmax and significantly decreased clearance in HBN mice). Similar to data obtained with the drug mixture administered intravenously, the pattern of metabolite production in the HBN animals showed a delay in maximal levels of circulating metabolites (supplemental Fig. 5).
###end p 53
###begin p 54
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
Using the oral and intravenous dosing data, percentage bioavailability was calculated (Table 2). HBN animals showed a 4-fold increase in midazolam bioavailability, whereas for phenacetin, metoprolol, and chlorzoxazone, bioavailability was very low in the wild-type animals (<4%) and unaltered in the nulls. When dosed as part of the drug mixture, tolbutamide bioavailability in the HBN mice was decreased by approximately50% as compared with wild type; however, when orally dosed as a single agent and recalculated, both wild-type and HBN animals showed >100% bioavailability.
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 116 124 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 152 159 152 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
All previously published work on the effects of cytochrome b5 on NADPH-dependent P450 activity has been carried out in vitro. In order to establish the in vivo role of this hemoprotein in drug disposition, we have generated a mouse where this enzyme has been conditionally inactivated in the liver.
###end p 56
###begin p 57
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 186 187 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 222 229 222 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 234 237 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ALB</sup>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre<sup>ALB</sup></italic>
###xml 138 142 <span type="species:ncbi:10090">Mice</span>
To exclude the possibility that a global deletion of microsomal cytochrome b5 would be lethal, a conditional targeting strategy was used. Mice deleted for hepatic microsomal cytochrome b5 developed normally, with the Cytb5lox/lox::CreALB genotypes being found in Mendelian proportions. No alterations in liver morphology, hepatic lipid content, or hepatic serum markers were observed.
###end p 57
###begin p 58
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 46 48 46 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b<sub>5</sub></italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 132 125 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 298 313 298 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>B</italic> and <italic>C</italic></xref>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 631 632 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 632 633 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 684 692 684 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 694 700 694 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 705 712 705 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 829 830 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 832 833 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 1196 1197 1196 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1197 1198 1197 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1312 1320 1312 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1355 1362 1355 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 1470 1471 1470 1471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1469 1471 1469 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 1556 1557 1556 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1557 1558 1557 1558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1873 1874 1873 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1874 1875 1874 1875 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1940 1941 1940 1941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1939 1941 1939 1941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 1997 1998 1997 1998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1998 1999 1998 1999 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 987 991 <span type="species:ncbi:10090">mice</span>
The hepatic deletion of microsomal cytochrome b5 was shown to be both specific and essentially complete by Western blotting (Fig. 1A) and, importantly, unlike the hepatic deletion of cytochrome P450 reductase (23, 42), did not result in significantly increased expression of hepatic P450 proteins (Fig. 1, B and C). These data indicate that at the time points studied, a reduction in P450 activity, as a consequence of microsomal cytochrome b5 deletion, is not compensated by an increase in P450 expression. The use of a range of both model substrates and probe drugs clearly demonstrated that the absence of microsomal cytochrome b5 significantly attenuated P450-mediated metabolism in vitro (Fig. 2 and Table 1). The extent of suppression of enzyme activity varied markedly between substrates, as has been previously reported (2, 6). For all fluorocoumarin substrates employed, there was a highly significant decrease in NADPH-mediated P450 metabolism in liver microsomes from the HBN mice (as high as 90% for EFC), whereas for the two resorufin analogues and bufuralol, the change was still significant (at least 50% decrease for each compound) but less marked. This variability in cytochrome b5 effects was further illustrated by the use of a series of probe drugs, where the kinetic parameters defining the in vitro metabolism were markedly changed (Table 1). For all substrates, with the exception of tolbutamide, the data followed Michaelis-Menten kinetics, and Km values were essentially unchanged in the HBN samples. This suggests that cytochrome b5 binding does not cause a conformational change in the structure of the P450s responsible for this metabolism. In contrast, in both wild type and HBN samples, the data for tolbutamide oxidation did not fit Michaelis-Menten kinetics, exhibiting negatively cooperative binding. Furthermore, the removal of cytochrome b5 had a pronounced effect on tolbutamide binding, decreasing the Km by 68-fold, indicating that the presence of cytochrome b5 does affect tolbutamide binding.
###end p 58
###begin p 59
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 15 18 15 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 220 221 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 324 325 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 404 407 404 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 560 567 560 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 598 599 598 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
In all cases, Vmax values were substantially reduced by the removal of cytochrome b5 (range 1.7-20-fold lower for acetaminophen and 4-hydroxymidazolam production, respectively), implying that the presence of cytochrome b5 is critical for optimal turnover in the P450s investigated. Interestingly, the effects of cytochrome b5 were different dependent on the site of metabolism (e.g. with midazolam, the Vmax for oxidation at the 1- versus 4-hydroxy sites was 29 versus 5% of the control, respectively). A similar effect was also seen for metoprolol oxidation (Table 1), indicating that cytochrome b5 effects show specificity for different sites of oxidation.
###end p 59
###begin p 60
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 449 450 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 668 669 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 692 693 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 706 714 706 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 803 804 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 804 805 804 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
These findings provide strong genetic evidence that the modulatory effects of cytochrome b5 are both substrate- and P450-dependent and that the activities of many P450 enzymes are affected by this protein. Similar reductions in P450 activities (60-70%) have also been demonstrated using antibodies to cytochrome b5, both in microsomal fractions and with purified protein (43, 44). Furthermore, the addition of recombinant membrane-bound cytochrome b5 to HBN liver microsomes led to a concentration-dependent increase of catalytic activities toward BFC and chlorzoxazone, indicating that the loss of activity in HBN samples was indeed due to the absence of cytochrome b5 (supplemental Fig. 2, B and C). The in vitro data generated from the probe drugs suggests that in general, the absence of cytochrome b5 results in reduced rates of P450-mediated metabolism.
###end p 60
###begin p 61
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 355 356 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 358 364 358 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 534 535 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 535 536 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 680 681 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 681 682 681 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 844 845 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 845 846 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
It is interesting to note that in some cases the fluorocoumarin substrates and tolbutamide NADH-mediated metabolism were essentially abolished in HBN mice, whereas for the other compounds, residual activity remained (e.g. in the case of ER or BR), indicating the existence of an alternative metabolic pathway involving NADH but independent of cytochrome b5 (Fig. 2). One possible explanation for the residual activity could be the presence of an alternate electron donor, such as the recently described outer mitochondrial cytochrome b5, which is derived from a gene locus on chromosome 8 (45, 46) and encodes for a protein of 16.3 kDa, slightly larger than microsomal cytochrome b5 at 15.2 kDa and approximately45% identical at the amino acid level. However, to date, there is no evidence for the interaction of outer mitochondrial cytochrome b5 with the microsomal P450 system.
###end p 61
###begin p 62
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 365 366 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 413 414 413 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
Recently, a novel, soluble, NAD(P)H reductase (NAD(P)H cytochrome b5 oxidoreductase), located in the lumen of the endoplasmic reticulum, was reported (47), which contains both cytochrome b5 and cytochrome b5 reductase domains. In order to confirm that this enzyme was not induced in the HBN mice, and potentially compensating for the loss of microsomal cytochrome b5, we obtained antiserum to NAD(P)H cytochrome b5 oxidoreductase; immunoblotting liver samples from wild-type and HBN mice found no difference in expression levels (data not shown). Li and Porter (48) have also described a second microsomal reductase, which is active with squalene monooxygenase and apparently capable of supporting up to 40% of the activity of this enzyme, although the identity of this reductase and its interactions with other enzymes remain unclear.
###end p 62
###begin p 63
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 225 226 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
In addition, due to its role in fatty acid desaturation, it is possible that changes in the phospholipid bilayer, as observed in stearoyl-CoA-desaturase null mice (49), are responsible for the observed effects of cytochrome b5 on P450 metabolism. However, no changes in the fatty acid composition of endoplasmic reticulum membranes from wild-type and HBN mice were found (supplemental Fig. 3).
###end p 63
###begin p 64
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 547 555 547 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 632 633 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 397 402 <span type="species:ncbi:10090">mouse</span>
In order to establish the in vivo effects of the hepatic cytochrome b5 deletion, we administered a series of probe drugs by both intravenous and oral routes to control and HBN mice. These drugs were chosen because they have been shown to be metabolized in a number of species by different cytochrome P450s. The interpretation of such experiments is inevitably complex, particularly because in the mouse there is little background historical information on the key factors that define their pharmacokinetic parameters. However, consistent with the in vitro studies, in general, it was evident that the deletion of hepatic cytochrome b5 caused marked changes in drug pharmacokinetics independent of the route of administration.
###end p 64
###begin p 65
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 223 224 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 323 324 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 776 784 776 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 807 814 807 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 833 834 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 834 837 834 837 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1101 1109 1089 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
When administered intravenously, the terminal half-life was increased in HBN mice for all drugs used (Table 2). This increase is consistent with decreased liver metabolism as a consequence of hepatic microsomal cytochrome b5 deficiency and provides the first evidence that strongly supports the conclusion that cytochrome b5 plays a role in in vivo P450-mediated drug metabolism. In addition, the profiles of metabolite production for midazolam, phenacetin, and metoprolol were different between HBN and wild-type mice; for example, maximal metabolite levels of 1'-hydroxymidazolam occurred 3 times more slowly in HBN mice than in wild type (120 versus 40 min) when dosed intravenously (supplemental Fig. 5). These differences in metabolite production are consistent with the in vitro kinetic data shown in Table 1. For example, the Vmax values for 1'-hydroxymidazolam were approximately3 times higher in wild type as compared with HBN. No major differences in the formation of the demethyl metabolite of metoprolol were observed at the early time points between HBN and wild-type mice, despite major in vitro differences (supplemental Fig. 5 and Table 1).
###end p 65
###begin p 66
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 318 319 318 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 421 428 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 831 834 831 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
Following oral administration of the drug mixture, the interpretation of pharmacokinetic parameters is more complex due to factors such as the absorption across gastrointestinal tract and hepatic blood flow. This added complexity was manifest in the fact that for some drugs, such as midazolam, microsomal cytochrome b5 deficiency and the consequent reduction in hepatic metabolism can lead to increased bioavailability (Table 2) as well as a decreased rate of elimination. These alterations in pharmacokinetics could therefore potentially lead to an exaggerated response to the drug. However, for the other drugs, first pass liver metabolism does not appear to be important in determining bioavailability, which is presumably dependent primarily on efficiency of gastrointestinal absorption or metabolism. When dosed orally, the Cmax appears to be the most reliable indicator of a change in metabolizing capacity and acts as a valuable corollary to the increased half-life observed following intravenous administration.
###end p 66
###begin p 67
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 180 188 180 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 467 475 467 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 484 491 484 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 668 669 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
In summary, mice with a hepatic deletion of microsomal cytochrome b5 display a significant change in the metabolism of a range of substrates by a number of cytochrome P450 enzymes in vitro and, more importantly, in vivo. The data presented in this report suggest that the level and/or activity of hepatic microsomal cytochrome b5 can play a significant role in the metabolism, disposition, and therapeutic effectiveness of clinically used drugs. The extrapolation of in vitro data to in vivo and the relative importance to drug pharmacokinetics and disposition are very complex and involve a wide range of parameters that could include the cytochrome P450/cytochrome b5 ratio, the cytochrome P450 enzyme involved, the substrate concentration, the P450 turnover number, and the overall role of cytochrome P450 metabolism as a rate-limiting factor in drug disposition.
###end p 67
###begin title 68
Supplementary Material
###end title 68
###begin title 69
[Supplemental Data]
###end title 69
###begin p 70
We thank Catherine Hughes and Susanne van Schelven for excellent technical assistance.
###end p 70
###begin p 71
###xml 161 164 161 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
The abbreviations used are: POR, cytochrome P450 oxidoreductase; AUC, area under the curve; BFC, 7-benzyloxy-4-trifluoromethylcoumarin; BR, benzyloxyresorufin; Cmax, maximum concentration of drug achieved in the blood after dosing; EFC, 7-ethoxy-4-trifluoromethylcoumarin; ER, ethoxyresorufin; HBN, hepatic microsomal cytochrome b5 null; HPLC, high performance liquid chromatography; MFC, 7-methoxy-4-trifluoromethylcoumarin; LC-MS/MS, liquid chromatography-tandem mass spectrometry.
###end p 71
###begin p 72
C. R. Wolf, unpublished results.
###end p 72

